New hope for esophageal cancer: triple therapy trial launches
NCT ID NCT07251062
First seen Dec 02, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This study tests a new combination of drugs (SYS6010 and SG001) with or without chemotherapy as a first treatment for people with advanced or metastatic esophageal squamous cell carcinoma. About 737 adults aged 18-75 who have not had prior treatment for advanced disease will participate. The goal is to see if the combination shrinks tumors and improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.